Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 11/20 | 0.54 |
| ▸ | SELP | P16109 | 8/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077057 | 0.92 | SELE (0.57) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12631208 | 0.89 | SELE (0.53) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12630624 | 0.86 | SELE (0.58) | SELESELP | |
| SCHEMBL14217740 | 0.82 | SELE (0.59) | SELESELP | |
| SCHEMBL9613558 | 0.80 | SELE (0.75) | SELESELP | |
| SCHEMBL13077385 | 0.79 | SELE (0.49) | SELELGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL9613583 | 0.79 | SELE (0.68) | SELESELP | |
| SCHEMBL11982061 | 0.78 | SELE (0.60) | SELESELP | |
| SCHEMBL12239769 | 0.78 | SELE (0.59) | SELESELPLGALS3LGALS9LGALS1 | |
| SCHEMBL12240054 | 0.78 | SELP (0.51) | SELESELPLGALS3LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7964569-B2 | Oligosaccharide mimetics such as {(1R,2R,3S)-2-[(6-Deoxy- alpha -L-Galactopyranosyl)Oxy]-3-Ethyl-Cyclohex-1-yl}2-O-Benzoyl-3-O-[(1S)-1-Carboxy-2-Cyclohexyl-Ethyl]- beta -D-Galactopyranoside | GLYCOMIMETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | FUT6, B3GNT2, FUT5 | SELE 622/4885SELP 860/4885LGALS3 79/4885 |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | FUT6, ENGASE, FUT5 | SELE 158/4885SELP 260/4885LGALS3 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.